Event Participants
Executives
1
Sagar Girish Bhanushali (Chairman & CFO)
Analysts
9
Akhil Parekh (360 One Capital), Amit Joshi (Individual Investor), Deepak Poddar (Sapphire Capital), Devi Shraji (Zen Partners), Harshit Pandey (Blue Star Capital), Hrishit Jhaveri (CBA Asset Managers), Kashyap Desai (Richbond Capital), Masood (Individual Investor), Surendra Reddy (Chartered Investors Community)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹96.9 crores | +86.3% YoY, driven by strong demand across product portfolio and growth strategies |
| EBITDA | ₹11.5 crores | +97.7% YoY; margin improved 70 bps to 11.9% despite aluminum price volatility |
| PAT | ₹7.6 crores | +98.8% YoY; PAT margin expanded 80 bps to 7.9% |
| Monthly Revenue Run Rate (Q1 exit) | ~₹35 crores/month | Ahmedabad contributing ₹6-7 crores/month of total |
| Ahmedabad Capacity Utilization | 35% | Ramping up with customer approvals; target 80%+ by end of FY27 |
| Vasai Plant Capacity Utilization | 85% | Peak monthly revenue potential ₹32-35 crores |
| Receivables (June) | ₹77 crores | Normalized within 75-80 day range after March/April spike |
| Employee Count | ~100 | Vasai 53-54, Ahmedabad 28-29, ROPP unit 13; 25-30 more for new export unit |
| Total Debt | Near zero (0.6% D/E) | Planning additional debt of ₹40-50 crores for expansion |
| FY26 Employee Cost | ₹2.25 crores | 18-20% was director remuneration; no director salary taken in Q1 FY27 |
| Gross Margin | 15-16% | Management sees scope for improvement with operating leverage |
Geographic & Segment Commentary
Aluminum Foil (Blister & Strip) - Domestic: Core business continues strong with 86.3% YoY revenue growth. Vasai plant operating at 85% capacity with peak monthly potential of ₹32-35 crores. Ahmedabad plant at 35% utilization, contributing ₹6-7 crores monthly; management targeting 80% capacity (₹30 crores/month) by March FY27. Demand driven by expanding pharma exports and regulatory compliance requirements.
ROPP Caps (New Vertical): Strategic entry via MOU with WPL Solutions. Manufacturing began with first billing in July. Annual peak capacity ₹55-60 crores with higher margin profile (18-20% takeaway margin industry standard). Low capital requirement (~₹50-60 lakhs) and labor intensity (13 employees). Management expects ₹30-35 crores revenue in FY27 and ₹60-65 crores in FY28.
Export Business (Unit 4 - Planned): Acquiring running plant from Vapi/Sarigam area to relocate to Vasai. Capacity of ₹4-10 crores/month with ~70% spare capacity. Target markets include Nigeria, South Africa, Ghana, Zimbabwe - key hubs for Indian pharma foil exports. Plant is export-compliant. Production expected by end of August. Strategic rationale: learn export SOPs via merchant exporters before direct entry.
Company-Specific & Strategic Commentary
Regulatory Tailwinds: Implementation of Aluminum and Aluminum Alloy Products Quality Control Order 2026 with mandatory BIS certification for pharma aluminum foil expected to transform competitive landscape. Positioned to benefit as quality-focused manufacturer with compliant facilities.
Capacity Expansion Roadmap: Current combined peak potential ₹750-800 crores annually (Vasai ₹300-350 crores, Ahmedabad ₹350-400 crores, Mumbai/ROPP ₹50-60 crores). Management targeting full capacity by FY28, with ₹450-500 crores revenue goal for FY27.
Procurement Advantage: All raw material (bare aluminum foil in 20/25/30/40 microns) sourced domestically from 12-15 rolling mills due to anti-dumping duty. Creditor payment terms improved to 25-30 days, a competitive advantage versus peers who must pay in advance.
Customer Strategy: 100+ clients with strict concentration limits - no client comprises 10-20% of topline. Top clients: Unity Foil, Krish Pharmafoils, McCoy Pharma, Maxiel. New clients onboarded gradually (₹50 lakhs initial, scaling to ₹1-1.5 crores based on performance).
Promoter Commitment: One promoter (Mohansingh Parmar) sold 12% stake for personal requirements, disclosed to NSE; all shares voluntarily locked for 1.5 years with no further selling.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue | ₹450-500 crores | Based on achieving Q1 run rate maintenance plus Ahmedabad ramp-up; zero-growth scenario still crosses ₹400 crores |
| FY28 Revenue | ₹750-800 crores | Requires all four units operating at 80-100% capacity; funding from ₹40-50 crores additional debt and ₹35-38 crores internal accruals |
| Ahmedabad Utilization | 80%+ by March FY27 | Customer approvals, order book inflows, and pharma engagement driving ramp-up |
| EBITDA Margin | ~12% sustainable | Management confident of maintaining Q1 levels in Q2 and Q3; export vertical may enhance margins |
| FY27 PAT | ~₹35 crores | Implied from working capital discussion (₹7.5 crores quarterly run rate) |
| ROPP Caps Revenue | FY27: ₹30-35 crores; FY28: ₹60-65 crores | Ramping to peak capacity over 12 months |
| Unit 4 (Export) Production | Start by end of August 2026 | Plant relocation from Vapi/Sarigam to Vasai; already export-compliant |
Risks & Constraints
| Risk | Context |
|---|---|
| Aluminum Price Volatility | Middle East tensions drove aluminum to multi-year highs in Q1 before stabilizing. Management mitigates via lean inventory (1-1.5 months on rising trends, reduced purchases on downtrends) and fast conversion cycles (10-12 days). Inventory risk exists on unsold stock at month-end. |
| Working Capital Strain | Fast growth (80-90% YoY) keeps operating cash flow negative due to inventory carrying and debtor cycle (100-120 days with pharma clients). Management not prioritizing positive cash flow while scaling. Additional debt of ₹40-50 crores being arranged. |
| Export Market Execution | New to export markets; relying on merchant exporters initially to learn SOP requirements, regulatory standards, and packaging specifications for US/EU markets. Direct entry planned only after 5-6 months of learning. Payment secured via LC (30-45 days). |
| Customer Concentration | Mitigated by policy limiting any single client's share; 100+ client base with monthly volume limits per client. Top client changes quarterly. |
| Director Remuneration Overhang | No director salary taken in Q1; FY26 compensation was ~18-20% of employee costs. Future withdrawals could increase expense base. |
Q&A Highlights
Capacity and Revenue Trajectory
- Question: With Ahmedabad at ₹6-7 crores monthly now, reaching 80% utilization implies ₹55-60 crores monthly run rate by Q4? (Deepak Poddar)
- Answer: Confirmed. Combined plant potential of ₹750-800 crores, targeting that in FY28. FY27 revenue guided at ₹450-500 crores. (Sagar Bhanushali)
Margin Sustainability
- Question: Given aluminum price pressure in Q1, how should we view margins going forward? (Deepak Poddar)
- Answer: 12% EBITDA margin is 100% sustainable. Aluminum procurement uses lowest-level inventory on downward trends; conversion takes only 10-12 days, limiting inventory risk. Q2 and Q3 margins expected at same level. (Sagar Bhanushali)
Funding for Expansion
- Question: For ₹750-800 crores FY28 topline, will borrowing need to increase? (Akhil Parekh)
- Answer: Additional debt of ₹40-50 crores plus internal accruals of ₹35-38 crores (at ~₹35 crores PAT for FY27) provides ~₹70-80 crores fresh funds, sufficient for the targeted scale. (Sagar Bhanushali)
Working Capital and Cash Flow
- Question: Even at ₹600-700 crores scale, will cash flow remain negative? (Hrishit Jhaveri)
- Answer: Yes, that's expected at 80-90% growth pace. Negative cash flow is due to inventory and debtor cycle. At 20-30% growth, cash flow would turn positive within 1-2 years. Industry requires credit sales - no cash buyers exist. (Sagar Bhanushali)
ROPP Caps Margins
- Question: What margin range for the caps business? (Akhil Parekh)
- Answer: Industry takeaway margins of 18-20% with 35-40 day credit. Higher margins than foil business, but revenue capped at ₹50-60 crores annually at peak. (Sagar Bhanushali)
Export Strategy
- Question: How will you enter export markets - which products and which markets? (Akhil Parekh, Hrishit Jhaveri, Masood)
- Answer: Acquiring running plant already compliant for exports. Initially selling to merchant exporters (Nigeria, South Africa, Ghana, Zimbabwe hubs) with payment in 30-45 days via LC. Learning export SOPs before direct entry to US/EU markets. Same product line - aluminum foil rolls and strips. (Sagar Bhanushali)
Promoter Stake Sale
- Question: Promoters sold 12% stake in Q1 - reason? (Devi Shraji)
- Answer: Personal requirement of one promoter (Mohansingh Parmar), already disclosed to NSE. Not company-related. All shares voluntarily locked for 1.5 years; no further selling. Company fundamentals and expansion on track. (Sagar Bhanushali)
Raw Material Sourcing
- Question: Where do you source raw materials - domestic or import? (Deepak Poddar)
- Answer: 100% domestic due to anti-dumping duty. Procure bare aluminum foil in 20/25/30/40 microns from 12-15 rolling mills (who buy foil stock from Hindalco). Nalco not directly in pharma; Hindalco charges high premium, so sourcing via rolling mills. Creditor payment terms improved to 25-30 days. (Sagar Bhanushali)
Mumbai Facility Details
- Question: What's the capex for the Mumbai (ROPP) facility? (Deepak Poddar)
- Answer: Already running plant; only ₹50-60 lakhs capex if everything goes well in 6-8 months. Revenue already started - first bill raised two days ago. (Sagar Bhanushali)
Client Concentration
- Question: Could any client become too large as you scale to ₹750-800 crores? (Akhil Parekh)
- Answer: No - each client has strict limits, no single client comprises 10-20% of topline. Current 100+ client base with monthly volume caps per client. Top clients (Unity Foil, Krish Pharmafoils, McCoy Pharma, Maxiel) change quarterly. (Sagar Bhanushali)
Key Takeaway
GSM Foils delivered another strong quarter with revenue of ₹96.9 crores (+86.3% YoY), EBITDA of ₹11.5 crores (+97.7%, 11.9% margin), and PAT of ₹7.6 crores (+98.8%, 7.9% margin), navigating aluminum price volatility through disciplined inventory management. The company is executing a multi-pronged expansion: ramping Ahmedabad from 35% toward 80% utilization by March FY27, entering high-margin ROPP caps (18-20% margins, targeting ₹30-35 crores FY27 revenue), and acquiring an export-compliant plant (₹4-10 crores/month capacity) for strategic entry into African pharma foil markets. Management guided FY27 revenue of ₹450-500 crores and FY28 topline of ₹750-800 crores, funded by ₹40-50 crores additional debt and ~₹35 crores internal accruals. Regulatory tailwinds (BIS mandatory certification) favor quality-focused organized players. Watch items include working capital intensity (100-120 day receivable cycle), aluminum price direction, and execution of the export learning curve before direct market entry.